Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been given an average rating of “Moderate Buy” by the eleven research firms that are currently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $101.8571.

A number of equities research analysts recently weighed in on LNTH shares. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $94.00 price objective on shares of Lantheus in a research report on Thursday, May 7th. Weiss Ratings restated a “hold (c)” rating on shares of Lantheus in a research note on Tuesday, May 26th. Mizuho raised their target price on shares of Lantheus from $100.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, May 27th. Finally, B. Riley Financial restated a “buy” rating on shares of Lantheus in a research note on Friday, May 1st.

Lantheus Price Performance

NASDAQ LNTH opened at $96.30 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83. The firm’s 50 day moving average price is $86.04 and its 200-day moving average price is $73.80. Lantheus has a 52-week low of $47.25 and a 52-week high of $103.89. The company has a market cap of $6.27 billion, a PE ratio of 23.20 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The company had revenue of $377.33 million for the quarter, compared to the consensus estimate of $354.48 million. During the same quarter last year, the company earned $1.53 earnings per share. The firm’s revenue for the quarter was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Sell-side analysts forecast that Lantheus will post 4.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Lantheus

Several institutional investors have recently bought and sold shares of the company. Quantbot Technologies LP acquired a new stake in Lantheus in the third quarter worth about $1,847,000. American Assets Inc. acquired a new stake in Lantheus in the third quarter worth about $872,000. Assetmark Inc. boosted its holdings in Lantheus by 20.1% in the third quarter. Assetmark Inc. now owns 118,503 shares of the medical equipment provider’s stock worth $6,078,000 after acquiring an additional 19,844 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Lantheus by 1.7% in the third quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock worth $356,590,000 after acquiring an additional 115,338 shares in the last quarter. Finally, Heron Bay Capital Management acquired a new stake in Lantheus in the third quarter worth about $861,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.